提到“淋巴瘤”，很多人第一反应是“癌症”、“绝症”，甚至是“没救了”。但其实，这样的认知已经过时了！现代医学的飞跃让一些淋巴瘤变成了可以长期控制、甚至治愈的疾病。今天，我们就来认识三种“治愈率非常高”的淋巴瘤——它们是： ...

Blood-cancer medicine, manufactured in the US, won conditional approval for sale in mainland China last month.

A 2012 study of patients with low-tumor-burden follicular lymphoma showed that the 4-year freedom from treatment failure rate of watch-and-wait patients was not inferior to that o ...

Researchers sought to determine whether mosunetuzumab would have long-term efficacy in patients with follicular lymphoma.

Follicular lymphoma is a diverse disease, both biologically and clinically. Patients may present with indolent, asymptomatic disease or more aggressive, symptomatic disease with high tumor burden.

Follicular lymphoma is an indolent malignancy with a generally favorable prognosis, with survival often measured in decades. Yet up to 20% of patients develop early progression after starting ...

Two clinical trials testing the antibody loncastuximab tesirine (Zynlonta) showed encouraging results in patients with high-risk forms of two blood cancers—follicular lymphoma and marginal zone ...

Despite being declared cancer-free after initial treatment, I grapple with survivor's guilt, questioning why my lymphoma responded to therapy while others did not. When I started receiving treatment ...

Use of certain cancer drugs declines significantly after the emergence of negative confirmatory trial data, even though the medications remain available through off-label use.

Novartis' CAR-T Kymriah has become the first therapy in the category to be approved for the treatment of relapsed/refractory follicular lymphoma, ahead of Gilead Sciences' rival Yescarta.

The FDA granted Crispr Therapeutics (CRSP) orphan status for its treatment of follicular lymphoma.Don't Miss Our End of Quarter Offers: ...